XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
10. Segment Information Segment Reporting
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION
Information regarding operating segments for the three months ended September 30, 2022 and 2021 is as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Segment net sales 2022$317.9 $361.9 $1.0 
 2021$373.5 $372.2 $1.3 
Segment net profit (loss)2022$45.7 $36.0 $(0.6)
 2021$105.8 $50.7 $(0.2)
Information regarding operating segments for the nine months ended September 30, 2022 and 2021 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Segment net sales 2022$987.5 $1,081.4 $3.1 
 2021$1,074.2 $1,111.0 $4.6 
Segment net profit (loss)2022$183.5 $148.0 $(1.5)
 2021$272.7 $108.9 $(0.4)

Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses, interest expense and corporate overhead as directly supporting the strategies of our segments.

The following reconciles total segment profit to consolidated income (loss) before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2022202120222021
Total segment profit $81.1 $156.3 $330.0 $381.2 
Foreign currency exchange gains (losses), net(4.4)(2.2)(3.1)(0.5)
Gains (losses) from change in fair market value of equity securities and loan receivable(289.0)4,868.7 (6,172.3)7,078.8 
Other income (expense), net3.1 (0.6)42.3 16.7 
Consolidated income (loss) before income taxes$(209.2)$5,022.2 $(5,803.1)$7,476.2